| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065 | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378] | Technology appraisal guidance | TBC |
| Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232 | Technology appraisal guidance | TBC |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354 | Technology appraisal guidance | TBC |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339] | Technology appraisal guidance | |
| Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247] | Technology appraisal guidance | TBC |
| ALXN1840 for treating Wilson disease TS ID 9950 | Technology appraisal guidance | TBC |
| Alzheimer's disease (early) - gantenerumab [ID6142] | Technology appraisal guidance | TBC |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Technology appraisal guidance | |
| Amyotrophic lateral sclerosis - SAR443820 [ID6386] | Technology appraisal guidance | TBC |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance | TBC |
| Asunercept for treating glioblastoma [1301] | Technology appraisal guidance | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324] | Technology appraisal guidance | |
| Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203] | Technology appraisal guidance | TBC |
| Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152] | Technology appraisal guidance | TBC |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
| Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] | Technology appraisal guidance | TBC |
| Avelumab for previously treated platinum-resistant ovarian cancer ID1497 | Technology appraisal guidance | TBC |
| Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
| Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294] | Technology appraisal guidance | |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] | Technology appraisal guidance | TBC |
| Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 | Technology appraisal guidance | TBC |
| Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 | Technology appraisal guidance | TBC |
| Belzutifan for previously treated advanced renal cell carcinoma [ID6154] | Technology appraisal guidance | TBC |
| Benralizumab for previously treated severe nasal polyps [ID1659] | Technology appraisal guidance | TBC |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266] | Technology appraisal guidance | |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Technology appraisal guidance | |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462 | Technology appraisal guidance | |
| Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
| BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296] | Technology appraisal guidance | TBC |
| Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180] | Technology appraisal guidance | TBC |
| Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768] | Technology appraisal guidance | TBC |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma [ID6334] | Technology appraisal guidance | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Technology appraisal guidance | |
| Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ] | Technology appraisal guidance | TBC |
| Cabotegravir for preventing HIV-1 in adults and young people [ID6255] | Technology appraisal guidance | |
| Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
| Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474 | Technology appraisal guidance | |
| Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330] | Technology appraisal guidance | TBC |
| Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370] | Technology appraisal guidance | |
| Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383] | Technology appraisal guidance | TBC |